{
  "id": 5095444,
  "title": "Replimune Group stock hits 52-week high at 16.2 USD",
  "url": "https://urgent.news/2026/09/02/replimune-group-stock-hits-52-week-high-at-16-2-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T13:37:26.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/replimune-group-stock-hits-52week-high-at-162-usd-93CH-4886289"
  },
  "original_language": "en",
  "account": "Replimune Group Inc's stock soared to a 52-week high of $16.20, a testament to the company's impressive growth. The stock currently trades 1% below its peak, marking a significant 165.99% increase over the past year. Recent momentum has been especially strong, with a 119% gain in the past six months and a 61% return year-to-date. Analysts remain bullish, with price targets ranging from $14 to $24. However, InvestingPro analysis indicates the stock is currently overvalued. The FDA's accelerated approval of Replimune Group's cancer treatment, TUDRIQEV, combined with nivolumab, has propelled the company to new heights. This approval marks the first of an oncolytic virus combined with a checkpoint inhibitor for advanced melanoma. Following this breakthrough, Wedbush and Leerink both upgraded Replimune's stock rating to Outperform, raising price targets to $19 and $17 respectively. Cantor Fitzgerald echoed this optimism, reiterating an Overweight rating and highlighting Tudriqev's potential for advanced melanoma. As anticipation builds for Replimune's upcoming earnings report, the company's future in the biotech sector appears promising.",
  "summary": null,
  "key_points": [
    "Replimune Group stock reaches $16.20, a 52-week high",
    "FDA accelerated approval of TUDRIQEV with nivolumab boosts company",
    "Analysts upgrade to Outperform, citing Tudriqev's potential for melanoma"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Johnson and Johnson stock hits all-time high at 276.5 USD",
        "url": "https://urgent.news/2026/09/02/johnson-and-johnson-stock-hits-all-time-high-at-276-5-usd",
        "published": "2026-09-02T13:34:37.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}